News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Curis, Inc. (CRIS) To Release Second Quarter 2014 Financial Results And Hold Conference Call On August 7, 2014


7/31/2014 10:18:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its second quarter financial results on Thursday, August 7, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Daylight Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427, as well as its partnered programs, including Erivedge® (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the three- and six-month periods ended June 30, 2014.

To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 9:00 A.M. EDT. The conference ID number is 73498877. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.

About Curis, Inc.

Curis is an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Roche is also studying Erivedge in other diseases including relapsed/ refractory acute myelogenous leukemia (AML) and relapsed/ refractory high-risk myelodysplastic syndrome (MDS) as well as idiopathic pulmonary fibrosis (IPF). Curis partner Debiopharm is studying HSP90 inhibitor Debio 0932 in patients with advanced lung cancer. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 mmohindru@curis.com Michael P. Gray Chief Financial & Chief Business Officer Curis, Inc. 617-503-6632 mgray@curis.com

Curis, Inc. Logo


Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES